LipocineLPCN
13F holders, Q3 2024 (September 30)18holders −1
1new positions
2sold out
1famous investor
$4.49avg. 13F price*
At the end of Q3 2024, 18 institutions reported holding Lipocine Inc. (LPCN) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($994K), BlackRock, Inc. ($401K) and UBS Group AG ($267K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Lipocine Inc.
- CUSIP
- 53630X203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $54 |
| Exits | 2 | $106K |
All 13F filers, Q2 2024 → Q3 2024: 25,742 shares bought and 12,831 shares sold, net +12,911 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Vanguard Group Inc. | 0.00% | No change | 221,459 | $994K |
| BlackRock, Inc. | 0.00% | — | 89,272 | $401K |
| UBS Group AG | 0.00% | Add +5.7% | 59,413 | $267K |
| Geode Capital Management, LLC | 0.00% | Add +1.9% | 54,216 | $243K |
| Renaissance Technologies | 0.00% | Add +57.0% | 40,332 | $181K |
| Susquehanna International Group, LLP | 0.00% | Add +0.0% | 25,008 | $112K |
| State Street Corp. | 0.00% | No change | 18,626 | $84K |
| Dimensional Fund Advisors LP | 0.00% | Add +51.8% | 18,016 | $81K |
| Northern Trust Corp. | 0.00% | No change | 13,160 | $59K |
| Morgan Stanley | 0.00% | No change | 2,634 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +38.1% | 1,066 | $5K |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 471 | $2K |
| Group One Trading LLC | 0.00% | Add +2543.8% | 423 | $2K |
| Osaic Holdings, Inc. | 0.00% | No change | 227 | $1K |
| Clearstead Advisors, LLC | 0.00% | No change | 74 | $333 |
| Tidemark, LLC | 0.00% | No change | 59 | $265 |
| Bank of America Corp. | 0.00% | Add +27.3% | 56 | $252 |
| JPMorgan Chase & Co. | 0.00% | New | 12 | $54 |
"% of holder's portfolio" is LPCN's weight in each manager's 13F, not the share of Lipocine Inc. the manager owns.